Blokes / Joi
Blokes (men) and Joi (women), 'optimization' telehealth brands
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Platform; prescribes testosterone, enclomiphene, peptides, GLP-1
Reference only. Not medical advice.
What can go wrong
TRT and peptides are serious therapies with monitoring needs and fertility effects; many peptides on the menu are not FDA-approved and lack robust human data. Low entry pricing plus wide panels plus 'optimization' framing is a combination well-suited to converting healthy men into long-term subscribers. Some observers characterize the broad, lightly-gated model as potential telehealth overreach.
This is something to take to a clinician. The Atlas can tell you what is known about blokes / joi in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Blokes (for men) and its sister brand Joi (for women), operated together as Joi + Blokes and founded by Josh and Katy Whalen, are telehealth 'optimization' clinics that pair tiered lab panels (roughly $149-$699 covering 56-110 biomarkers) with a diagnostics-first workflow and a low-priced entry subscription (reported from about $99/month) that bundles clinician visits, quarterly labs, and testosterone cypionate. The menu extends to enclomiphene, peptides, oxytocin spray, and GLP-1 weight loss. The branding leans on 'optimization' and 'longevity' language rather than disease treatment.
The 'optimization and longevity' branding applied to the same TRT-and-peptides menu.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Same optimization playbook: broad panels create many flaggable results, low entry pricing reduces the barrier to starting, and bundled subscriptions maximize retention on lifelong-tending therapies. 'Optimization' and 'longevity' framing repositions ordinary hormone variation as something to be corrected.
'Optimization' is a marketing frame
There is no regulatory or consensus clinical definition of hormone 'optimization' or an 'optimal' testosterone level for an otherwise-healthy man. The term reframes replacement-for-deficiency (a medical indication) as enhancement-for-wellness (a lifestyle purchase), which broadens the addressable market well beyond men with genuine, symptomatic, guideline-defined hypogonadism.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks.
Replacement is not the same as a cycle
'Optimization' targeting implies pushing toward the top of, or above, the physiological range, which raises erythrocytosis and cardiovascular risk relative to true replacement dosing.
What it does to fertility
TRT suppresses spermatogenesis; enclomiphene is offered as a fertility-sparing alternative, itself off-label for the purpose.
What people get wrong
Often said'Optimizing' your hormones is a recognized medical goal
ActuallyThere is no consensus clinical definition of hormone optimization for a healthy man. 'Optimization' is a marketing frame that expands the market beyond diagnosed deficiency; it is not a guideline-endorsed indication.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Founders Josh and Katy Whalen; revenue from lab fees plus bundled recurring subscriptions.
At a glance
- Brands
- Blokes (men) / Joi (women), operated as Joi + Blokes
- Founders
- Josh and Katy Whalen
- Lab panels
- ~$149-$699, 56-110 biomarkers
- Entry subscription
- reported from ~$99/month (bundles meds, visits, labs)
- Menu
- TRT, enclomiphene, peptides, oxytocin, GLP-1
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Blokes / Joi. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.